Cover Image
Market Research Report

Psoriasis - 5EU Drug Forecast and Market Analysis to 2024

Published by GlobalData Product code 365842
Published Content info 213 Pages
Immediate Delivery Available
Price
Back to Top
Psoriasis - 5EU Drug Forecast and Market Analysis to 2024
Published: April 13, 2016 Content info: 213 Pages
Description

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

The 5EU contributed 31.6% of the global market share in the psoriasis market in 2014. Similarly to the US, the drug classes spanning the 5EU psoriasis market were: TNF inhibitors, an IL-12/IL-23 inhibitor, IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, a PDE-4 inhibitor, systemic therapies, biosimilars, and topical therapies.

Scope

  • Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Psoriasis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.
Table of Contents
Product Code: GDHC277CFR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Leading Prescribed Drugs and Treatment Guidelines
    • 4.1.3. Clinical Practice
  • 4.2. 5EU

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Enbrel (Etanercept)
    • 5.3.2. Humira (Adalimumab)
    • 5.3.3. Remicade (Infliximab)
    • 5.3.4. Stelara (ustekinumab)
    • 5.3.5. Cosentyx (Secukinumab)
    • 5.3.6. Otezla (Apremilast)
    • 5.3.7. Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
    • 5.3.8. Methotrexate
    • 5.3.9. Fumaderm (Fumaric Acid Esters)
    • 5.3.10. Alzumab (itolizumab)
    • 5.3.11. Other Therapeutic Drug Classes Used in Psoriasis
    • 5.3.12. Non-pharmacological Therapy

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Limited Patient Access Due to Drug Reimbursement Pattern
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Improved Drug Safety and Efficacy Profiles
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Education and Treatment of Psychological Factors Accompanying Psoriasis
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trials by Country
  • 7.3. Clinical Trials by Phase and Trial Status
  • 7.4. Promising Drugs in Clinical Development
    • 7.4.1. Xeljanz (Tofacitinib)
    • 7.4.2. Ixekizumab (LY2439821)
    • 7.4.3. Brodalumab
    • 7.4.4. Guselkumab (CNTO-1959)
    • 7.4.5. Tildrakizumab
    • 7.4.6. Piclidenoson (CF-101)
    • 7.4.7. Additional Phase III Pipeline Products
    • 7.4.8. Phase II Pipeline Products
    • 7.4.9. Phase I Pipeline Products
  • 7.5. Biosimilar Pipeline Products
    • 7.5.1. Introduction
    • 7.5.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 7.5.3. Biosimilars in the Immunology Community
    • 7.5.4. By the Numbers: Biosimilars in Development
    • 7.5.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 7.5.6. Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
    • 7.5.7. Biosimilars Forecast

8. Market Outlook

  • 8.1. 5EU
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Psoriasis Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Director of Therapy Analysis and Epidemiology
    • 9.7.5. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Immune Cells Involved in Lesions
  • Table 2: Symptoms of Psoriasis
  • Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
  • Table 4: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014
  • Table 5: Treatment Guidelines for Psoriasis
  • Table 6: Country Profile - 5EU
  • Table 7: Leading Treatments for Psoriasis, 2015
  • Table 8: Product Profile - Enbrel
  • Table 9: Enbrel Pivotal Study I Outcomes at 3 and 6 Months
  • Table 10: Enbrel pivotal study II outcomes at 3 Months
  • Table 11: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis
  • Table 12: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis
  • Table 13: Enbrel SWOT Analysis, 2015
  • Table 14: Global Sales Forecast ($m) for Enbrel, 2014-2024
  • Table 15: Product Profile - Humira
  • Table 16: Humira pivotal study outcomes at 16 weeks
  • Table 17: Humira SWOT Analysis, 2015
  • Table 18: Global Sales Forecast ($m) for Humira, 2014-2024
  • Table 19: Product Profile - Remicade
  • Table 20: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
  • Table 21: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16
  • Table 22: Remicade SWOT Analysis, 2015
  • Table 23: Global Sales Forecast ($m) for Remicade, 2014-2024
  • Table 24: Product Profile - Stelara
  • Table 25: Stelara Pivotal Study Outcomes at Week 12
  • Table 26: Stelara SWOT Analysis, 2015
  • Table 27: Global Sales Forecast ($m) for Stelara, 2014-2024
  • Table 28: Product Profile - Cosentyx
  • Table 29: Efficacy Endpoints in Cosentyx Phase III ERASURE Study
  • Table 30: Efficacy End Points in Cosentyx Phase III FIXTURE study
  • Table 31: Cosentyx SWOT Analysis, 2015
  • Table 32: Global Sales Forecast ($m) for Cosentyx, 2014-2024
  • Table 33: Product Profile - Otezla
  • Table 34: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2
  • Table 35: Otezla SWOT Analysis, 2015
  • Table 36: Global Sales Forecast ($m) for Otezla, 2014-2024
  • Table 37: Product Profile - Taclonex/Enstilar
  • Table 38: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.
  • Table 39: Taclonex/Enstilar SWOT Analysis, 2015
  • Table 40: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014-2024
  • Table 41: Product Profile - Methotrexate
  • Table 42: Methotrexate SWOT Analysis, 2015
  • Table 43: Global Sales Forecast ($m) for Methotrexate, 2014-2024
  • Table 44: Product Profile - Fumaderm
  • Table 45: Fumaderm SWOT Analysis, 2015
  • Table 46: Global Sales Forecast ($m) for Fumaderm, 2014-2024
  • Table 47: Product Profile - Alzumab
  • Table 48: Alzumab SWOT Analysis, 2013
  • Table 49: Global Sales Forecast ($m) for Alzumab, 2014-2024
  • Table 50: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015
  • Table 51: Dosing Guidelines for Broadband Ultraviolet B
  • Table 52: Dosing Guidelines for Narrowband Ultraviolet B
  • Table 53: Overall Unmet Needs in Psoriasis - Current Level of Attainment
  • Table 54: Psoriasis - Clinical Trials by Phase and Status, 2015
  • Table 55: Psoriasis - Phase Pipeline, 2015
  • Table 56: Comparison of Therapeutic Classes in Development for Psoriasis, 2015
  • Table 57: Product Profile - Xeljanz
  • Table 58: Xeljanz SWOT Analysis, 2015
  • Table 59: Global Sales Forecast ($m) for Xeljanz, 2014-2024
  • Table 60: Product Profile - Ixekizumab
  • Table 61: Efficacy Results of UNCOVER-2 at Week 12
  • Table 62: Efficacy Results of UNCOVER-3 at Week 12
  • Table 63: Ixekizumab SWOT Analysis, 2015
  • Table 64: Global Sales Forecast ($m) for Ixekizumab, 2014-2024
  • Table 65: Product Profile - Brodalumab
  • Table 66: Brodalumab SWOT Analysis, 2015
  • Table 67: Global Sales Forecast ($m) for Brodalumab, 2014-2024
  • Table 68: Product Profile - Guselkumab
  • Table 69: Guselkumab SWOT Analysis, 2015
  • Table 70: Global Sales Forecast ($m) for Guselkumab, 2014-2024
  • Table 71: Product Profile - Tildrakizumab
  • Table 72: Tildrakizumab SWOT Analysis, 2015
  • Table 73: Global Sales Forecast ($m) for Tildrakizumab, 2014-2024
  • Table 74: Product Profile - Piclidenoson (CF-101)
  • Table 75: Piclidenoson SWOT Analysis, 2015
  • Table 76: Additional Phase III Psoriasis Pipeline drugs, 2015
  • Table 77: Phase II Psoriasis Pipeline, 2015
  • Table 78: Phase I Psoriasis Pipeline, 2015
  • Table 79: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015
  • Table 80: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015
  • Table 81: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014-2024
  • Table 82: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014-2024
  • Table 83: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014-2024
  • Table 84: Sales Forecast ($) for Psoriasis in the 5EU, 2014-2024
  • Table 85: Key Events Impacting Sales for Psoriasis in the 5EU, 2014-2024
  • Table 86: Psoriasis Market in the 5EU - Drivers and Barriers, 2014-2024
  • Table 87: Key Launch Dates
  • Table 88: Key Patent Expiries
  • Table 89: Key Launch Dates
  • Table 90: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Psoriatic Plaque on Elbow of Patient
  • Figure 2: The Three Layers of the Skin and Associated Structures
  • Figure 3: Healthy Skin Versus Psoriatic Skin
  • Figure 4: Psoriasis Therapeutics - Ongoing Clinical Trial Sites by Country, 2015
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014-2024
  • Figure 6: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015
  • Figure 7: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014-2024
  • Figure 8: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014-2024
  • Figure 9: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014-2024
  • Figure 10: Sales for Psoriasis in the 5EU by Drug Class, 2014-2024
  • Figure 11: Sales for Psoriasis in the 5EU by Region, 2014-2024
Back to Top